TGF-β has been implicated as a major pathogenic factor in diabetic nephropathy. This
randomized, double-blind, phase 2 study assessed whether modulating TGF-β1 activity with
a TGF-β1–specific, humanized, neutralizing monoclonal antibody (TGF-β1 mAb) is safe and
more effective than placebo in slowing renal function loss in patients with diabetic
nephropathy on chronic stable renin-angiotensin system inhibitor treatment. We randomized
416 patients aged≥ 25 years with type 1 or type 2 diabetes, a serum creatinine (SCr) level …